Rating History for Moonlake Immunotherapeutics (MLTX) by Rothschild Redburn
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 3/19/2026 | Qize Ding | Upgrade | Buy (Neutral) |
40.00 (12.00) |
16.77 (19.68) |
17.35% | Details |
 |
|||||||
